These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2598 related articles for article (PubMed ID: 26254683)

  • 21. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
    von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
    Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
    Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
    Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
    Kato K; Machida R; Ito Y; Daiko H; Ozawa S; Ogata T; Hara H; Kojima T; Abe T; Bamba T; Watanabe M; Kawakubo H; Shibuya Y; Tsubosa Y; Takegawa N; Kajiwara T; Baba H; Ueno M; Takeuchi H; Nakamura K; Kitagawa Y;
    Lancet; 2024 Jul; 404(10447):55-66. PubMed ID: 38876133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study.
    Boers J; Joldersma A; van Dalsen AD; Wiegman EM; Schenk BE; de Graaf JC; Pierik EGJM; Timmer PR; de Groot JWB
    Ann Surg Oncol; 2020 May; 27(5):1520-1528. PubMed ID: 31828691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
    Crosby T; Hurt CN; Falk S; Gollins S; Mukherjee S; Staffurth J; Ray R; Bashir N; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G
    Lancet Oncol; 2013 Jun; 14(7):627-37. PubMed ID: 23623280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
    Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
    Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
    Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
    J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).
    Reynolds JV; Preston SR; O'Neill B; Baeksgaard L; Griffin SM; Mariette C; Cuffe S; Cunningham M; Crosby T; Parker I; Hofland K; Hanna G; Svendsen LB; Donohoe CL; Muldoon C; O'Toole D; Johnson C; Ravi N; Jones G; Corkhill AK; Illsley M; Mellor J; Lee K; Dib M; Marchesin V; Cunnane M; Scott K; Lawner P; Warren S; O'Reilly S; O'Dowd G; Leonard G; Hennessy B; Dermott RM
    BMC Cancer; 2017 Jun; 17(1):401. PubMed ID: 28578652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
    Conroy T; Galais MP; Raoul JL; Bouché O; Gourgou-Bourgade S; Douillard JY; Etienne PL; Boige V; Martel-Lafay I; Michel P; Llacer-Moscardo C; François E; Créhange G; Abdelghani MB; Juzyna B; Bedenne L; Adenis A;
    Lancet Oncol; 2014 Mar; 15(3):305-14. PubMed ID: 24556041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 130.